

The Chinese University of Hong Kong

Department of Biomedical Engineering



Time: 2:30 pm, 5 October 2018 (Friday)

Venue: Room 215, William M W Mong Engineering Building, CUHK

Biomarkers in Motor Neuron Diseases



Dr Ching-Hua LU, MD, PhD

Consultant Neurologist

Department of Neurology China Medical University Hospital Taiwan

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder, for which there is no effective treatment. Clinical trials in ALS are hindered by the lack of reliable biomarkers to enable an early diagnosis and monitoring of disease progression. There is therefore an urgent need to develop biomarkers for ALS. In this talk, I will firstly give an introduction of ALS and current biomarker developed in ALS. Then, I'll lead you through the development and progress of the current leading biomarker for ALS, neurofilament. Lastly, but not least, I'll update other potential markers in ALS.

Biography

Dr Ching-Hua LU is currently a consultant neurologist in the Department of Neurology, China Medical University Hospital in Taiwan. She received MD from China Medical University in 2001 and completed Neurology training in 2005. Then, she went to University College London for MSc in Neuroscience in 2007. She started researches for developing biomarkers for ALS at Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology from 2008 and completed her PhD training in 2013. She then received postdoctoral training at Blizard Institute, Queen Mary University of London between 2013 and 2016. During these years, she also contributed greatly in setting up and managing the first and by far the large biobank specific for MND biomarker researches in the UK. She moved back to Taiwan in 2016 and remains as an honorary clinical lecture at UCL Institute of Neurology. Her research focus is in developing biomarkers for neurodegenerative diseases and neuroinflammatory disorders.